Global Oncology Academy

Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU

ReachMD Healthcare Image

What are the outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide treatment? Tune in to find out.

  • Overview

    Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium. 

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free